All In Biotech

Drug Trial Radar · NCT07904806

Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

A Phase 2, Randomized, Double-blind, Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of VIS954 Administered Subcutaneously in Adult Participants With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Dec 15, 2026

Primary completion

Nov 20, 2029

Study completion Nov 20, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

Conditions

  • Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

  • VIS954Drug

    SC injection

  • Standard Of Care (SOC)Drug

    Glucocorticoids and rituximab or cyclophosphamide will be administered as standard-of-care induction therapy at the investigator's discretion and in accordance with local practice and applicable treatment guidelines.

  • PlaceboDrug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants in Remission at Week 24Time frame: Week 24
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs) Through Week 24Time frame: Baseline through Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.